Study of Epratuzumab in Systemic Lupus Erythematosus

UCB

Status and phase: Withdrawn; Phase 3

Conditions: Systemic Lupus Erythematosus

Treatments: Drug: Epratuzumab

Study type: Interventional

Funder types: Industry

Identifiers

NCT00382837

SL0005

EudraCT# 2006-003865-15

Details and patient eligibility

About

Epratuzumab is an investigational antibody designed to help treat SLE. The purpose is to evaluate safety and long term efficacy in concert with standard SLE treatments

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Must have completed SL0003 Alleviate A through 48 weeks

Exclusion criteria

• Development of toxicity to Epratuzumab
• Significant protocol deviations from SL0003 Study.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)